Loading market information…
HKSE · 2186.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 07:41 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Luye Pharma Group Ltd.’s quoted price sits in the lower half of its reported 52-week range, 51.68% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Luye Pharma Group Ltd.’s forward annual dividend is HK$0.06 per share, paid annual. The forward yield is 3.8% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Luye Pharma Group Ltd.’s next earnings report is currently expected on Mar 31, 2027, with estimated earnings per share of HK$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Luye Pharma Group Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| HK$0.11+2.36% vs estimate |
| HK$3.58B-49.83% vs estimate |
| Q2 2023 | Aug 30, 2023 | HK$0.04+35.41% vs estimate | HK$3.14B-2.33% vs estimate |
|---|
| Q4 2022 | Mar 30, 2023 | HK$0.10+48.12% vs estimate | HK$3.57B-48.93% vs estimate |
|---|
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
